1) The document discusses factors to consider when deciding whether to give maintenance therapy to NSCLC patients, including patient preference, risk of progression based on response to chemotherapy and EGFR status, performance status, and age. 2) It presents data from clinical trials showing that maintenance therapy can be more effective for NSCLC patients at high risk of progression, with one trial demonstrating improved overall survival for patients receiving erlotinib compared to placebo. 3) The document also discusses findings that maintenance gemcitabine did not provide a survival benefit compared to best supportive care for NSCLC patients with a performance status of 2.